Epistaxis in anticoagulated patients: Fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon - Sauter, T. C.; Hegazy, K.; Hautz, W. E.; Krummrey, G.; Ricklin, M. E.; Nagler, M.; Borner, U.; Exadaktylos, A. K. (Clin Otolaryngol, 2017)
OBJECTIVES: Treatment of epistaxis in patients on anticoagulants is challenging and associated with higher admission rates and longer hospital stays compared with patients without anticoagulation. However, there is little information about epistaxis in patients taking new direct oral anticoagulants such as rivaroxaban compared with patients on traditional vitamin K antagonists such as phenprocoumon. DESIGN: Retrospective cohort study. SETTING: The study was conducted at the emergency department of the University Hospital Inselspital, Bern, Switzerland. PARTICIPANTS: All admissions to the emergency department of the University Hospital Inselspital, Bern, Switzerland from 1st July 2012 to 30th June 2016 with non-traumatic epistaxis on anticoagulant therapy with phenprocoumon or rivaroxaban were included. MAIN OUTCOME MEASURES: We compared clinical outcome parameters (admission rates, length of hospital stay and mortality) for both anticoagulant groups. RESULTS: We included 440 patients with epistaxis, 123 (28%) on rivaroxaban and 317 (72%) on phenprocoumon. Fewer hospital admissions and shorter hospital stays were found in patients under rivaroxaban (12 (10.4%) vs 57 (18.0%) patients, P=.033; 0.7+/-2.2 vs 1.5+/-3.7 days, P=.011) compared with phenprocoumon. Anterior epistaxis was more common in the rivaroxaban group in contrast to posterior epistaxis in patients on phenprocoumon (74 (60.2%) vs 139 (43.8%) patients, P=.002; 7 (5.7%) vs 39 (12.3%) patients, P=.042). CONCLUSIONS: Our data suggests that epistaxis on direct oral anticoagulation with rivaroxaban is associated with shorter hospital stays and fewer hospital admissions than epistaxis on vitamin K antagonist phenprocoumon.
Keywords: journalArticle; *Risk Assessment; Aged; Anticoagulants/adverse effects; Epistaxis/*chemically induced/epidemiology; Factor Xa Inhibitors/adverse effects; Female; Follow-Up Studies; Humans; Incidence; Length of Stay/*trends; Male; Patient Admission/*trends; Phenprocoumon/*adverse effects; Retrospective Studies; Rivaroxaban/*adverse effects; Switzerland/epidemiology; anticoagulant; bleeding; coumarins; epistaxis; rivaroxaban